GH Research PLC (GHRS) Stock Score, Valuation & Financial Research

GH Research PLC is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for GHRS

GH Research PLC does not currently have a complete Wall Street Score. The stored market price is USD 21.52. These figures are a research snapshot, not a buy or sell recommendation.

What GH Research PLC does

GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients. Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disorders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

GH Research is a clinical-stage biopharmaceutical company focused on developing novel therapies for psychiatric and neurological disorders. The company currently operates as a research and development entity and does not generate revenue from product sales, relying instead on capital raises to fund its clinical pipeline.

Products and services

  • The company is developing a pipeline of product candidates, including GH001, an inhalable 5-MeO-DMT product candidate for treatment-resistant depression, and GH002, an injectable 5-MeO-DMT product candidate.

Business strengths to evaluate

  • Proprietary pipeline of 5-MeO-DMT product candidates Source

Business risks and research considerations

  • History of net losses and accumulated deficit Source
  • Status as a passive foreign investment company (PFIC) Source
  • Regulatory risks including potential clinical holds on INDs Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

GHRS financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 21.52
Market capitalization:
1.48B (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -62.27M
Free cash flow:
USD -43.67M
Cash:
USD 345.05M
Total debt:
USD 360K
EPS:
USD -1.00

What stands out

  • Free cash flow is USD -43.67M, negative for the stored period.
  • The balance sheet shows USD 345.05M of cash versus USD 360K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a missing revenue history warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 344.69M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for GHRS

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can GHRS fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is GHRS likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for GHRS to reach sustainable profitability?
  • What does the current missing revenue history warning mean for the reliability or interpretation of GHRS's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research GHRS

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.